Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    "Splenomegaly"
Show Display Options
Rank Status Study
1 Withdrawn Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly
Conditions: Hyper-reactive Malarial Splenomegaly;   Malaria;   Anaemia
Interventions: Drug: prednisone induction - chloroquine;   Drug: Chloroquine
2 Completed Estimation of Spleen by Residents With VScan
Condition: Splenomegaly
Intervention: Device: VScan Ultrasound (GE Healthcare, USA)
3 Completed Ultrasound Estimation of Spleen Size
Condition: Splenomegaly
Interventions: Device: Vscan Ultrasound (GE Healthcare, USA);   Device: Conventional Ultrasound
4 Completed Spleen Size in Peripheral Blood Stem Cell Donors
Condition: Splenomegaly
Intervention:
5 Recruiting CINC424A2X01B Rollover Protocol
Condition: Splenomegaly
Intervention: Drug: Ruxolitinib
6 Completed
Has Results
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
Conditions: Splenomegaly;   Pleural Effusion
Intervention: Device: resident with GE vscan
7 Recruiting The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
Conditions: Infectious Mononucleosis;   Splenomegaly
Intervention: Device: Point-of-care ultrasound
8 Completed Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Condition: Myelofibrosis
Intervention: Drug: SAR302503
9 Not yet recruiting Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Conditions: Leukemia;   Myelofibrosis;   Anemia;   Splenomegaly
Interventions: Drug: Rigosertib;   Behavioral: Questionnaire
10 Unknown  Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Conditions: Liver Cirrhosis;   Carcinoma, Hepatocellular;   Splenomegaly;   Laparotomy
Intervention:
11 Recruiting The Treatment of Hepatocirrhosis and Portal Hypertension
Condition: Hepatic Cirrhosis
Intervention: Procedure: PSE
12 Completed Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503;   Drug: Placebo
13 Completed Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
14 Not yet recruiting Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Conditions: Anemia;   Fatigue;   Fever;   Lymphadenopathy;   Lymphocytosis;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Plasma Cell Myeloma;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Pharmacological Study;   Drug: Ritonavir
15 Active, not recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Chronic Lymphocytic Leukemia;   Fatigue;   Fever, Sweat, and Hot Flashes;   Hepatomegaly;   Lymphadenopathy;   Lymphocytosis;   Small Lymphocytic Lymphoma;   Splenomegaly;   Thrombocytopenia;   Weight Change
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
16 Completed Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)
17 Unknown  Hemolysis in Patients With Hereditary Spherocytosis (HS)
Conditions: Hereditary;   Hemolysis
Intervention: Other: fermented papaya preparation (FPP)
18 Completed Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphoproliferative Disorder
Intervention: Drug: Fansidar (pyrimethamine and sulfadoxine)
19 Recruiting Natural History of Noncirrhotic Portal Hypertension
Conditions: Cystic Fibrosis;   Immunologic Deficiency Syndrome;   Turner Syndrome;   Congenital Hepatic Fibrosis;   Idiopathic Non-Cirrhotic Portal Hypertension
Intervention:
20 Completed
Has Results
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: ALPS;   Hypersplenism;   Lymphadenopathy
Interventions: Drug: Valproic Acid;   Procedure: CT Scan;   Procedure: Blood Sample

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.